Introduction: The present study aimed to assess the costs and consequences of using an
INTRODUCTION

Induction of labor (IOL) is the initiation of
contractions of the uterus in a pregnant woman who is not in labor, to help achieve a vaginal birth within 24-48 h. Indications and contraindications for IOL are provided in numerous clinical guidelines [1] . Where possible, data from RCTs was pooled and meta-analysis was conducted. Cochrane
Collaboration guidelines were applied [3] for quantitative analysis. To account for heterogeneity, a random-effects model was used. Heterogeneity of results was assessed using Q Cochran and I 2 statistical tests (StatsDirect software, version 2.6.8; StatsDirect
Limited, Cheshire, UK) [4] . Direct comparison of MVI versus DVI and indirect comparison (Bucher's method) via a common comparator (DVI), for MVI vs Dgel, Dtab and Foley [5, 6] were applied.
In case of oxytocin only, naïve indirect comparison was possible. Because of many limitations of this kind of approach, we resigned from presenting results for this comparison [7, 8] .
Relative risk (RR) was chosen as the parameter to assess clinical effectiveness and safety. The following outcomes were assessed: proportion of patients with vaginal delivery, proportion of patients with oxytocin use, proportion of patients with adverse events (uterine tachysystole, tocolytic administration, meconium in amniotic fluid, chorioamnionitis, and postpartum hemorrhage).
Reduction (or increase) in time from induction to labor and in time of labor due to MVI use versus comparators, was calculated on the basis of clinical data. Total time from induction to delivery and total time of labor for comparators were included in the model, as reported in country-specific questionnaires and reflecting local clinical practice.
Cost and Resource Use Data: Retrospective Study
The country-specific data used in the modeling were divided into two domains: costs and resource use. Real-world data (RWD) was obtained from clinical experts for the five countries of interest.
A comprehensive questionnaire was constructed in MS Excel 2007 and delivered to key opinion leaders or specialists experienced in gynecology and obstetrics.
A macro-costing method was chosen for data reporting. One completed questionnaire was received from each country.
The questionnaire sourced data for the average patient, taking into consideration the results of a review of patients' medical cards. After verification of completed questionnaires, all discrepancies were discussed and appropriate data were employed.
The following categories of unit costs were considered:
• Cost of interventions MVI, DVI, Dtab, Dgel and oxytocin;
• Cost of infusion fluid required for dissolving the oxytocin;
• Hourly rates of medical staff (nurse, midwife, obstetrician-gynecologist, anesthesiologist, neonatologist);
• Hourly cost of patient's stay in hospital wards: antenatal, labor (separately for vaginal and cesarean delivery) and postnatal (categories included all costs of procedures, disposables and non-medical resources apart from costs of drugs used for IOL and medical staff costs);
• Costs of adverse event treatment expressed as total, fixed costs of treatment.
Resource use in the model was generally divided into three time periods:
• Time from induction to (active) labor;
• Time of labor;
• Time from delivery to the hospital discharge.
The categories of resources (the same in each of mentioned time periods) taken into account in the modeling were as follows:
• Usage of the comparator per patient;
• Usage of supporting oxytocin; • Usage of infusion fluid required for dissolving oxytocin;
• Within the model, the differences in effectiveness and safety between MVI and comparators were applied to patients with IOL, producing differences in resource use and costs. The structure for time to labor and time to delivery is presented in Fig. 1 .
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. 
RESULTS
The
Results of the Literature Review
From the literature search, 11 RCTs out of 26 studies were included in the literature review and data synthesis (Wing [9] , Facchinetti [10] , [11] , Marconi [12] , Stewart [13] , Strobelt [14] , Rabl [15] , Cromi [16] , [17] , Edwards [18] , Jó źwiak [19] ) (Table 1 ). Although Cromi [16] concerned a double balloon catheter, the study was included, since it was shown that there were no significant differences in effectiveness or safety of ripening with a double balloon catheter when compared to Foley catheter [20, 21] . Further details on literature review search strategy can be found in supplementary material (S1).
For time-to-event end-points, only trials reporting both time to delivery and time to active labor/labor onset were included in the data synthesis and statistical calculations. This approach ensured reliability of the results. Therefore, trials which assessed only one of the end-points were excluded from the calculations because of the risk of potential bias on the model results. The following trials were eligible for statistical analysis: Wing [9] , Facchinetti [11] , Rabl [15] , Cromi [16] and [17] .
Since there were observed differences in the end points definitions, random effect model was used to perform a statistical analysis.
Results of head-to-head trials showed that for time to delivery and time to active labor, MVI was statistically significantly better than DVI (Wing [9] ), DVI was statistically significantly better than Dgel (Facchinetti [11] ), DVI was comparable to Dtab (Rabl [15] ) and Foley (meta-analysis of Cromi [14] and [17] ).
Detailed results are presented in Table 2 .
To reflect resource utilization of MVI versus the comparator, outcomes based on time-to-event end-points were recalculated as a reduction/increase, presented as the percentage of time (in hours) in the comparator arm. According to the calculations performed, use of MVI was related to a reduction both in time from induction to labor onset and time of labor.
On the basis of RR parameters (Table 3) , MVI seems to have similar performance on effectiveness and safety, since the differences in most of the outcomes did not reach statistical significance. Nevertheless, it was shown that MVI was related to significantly lower oxytocin use versus all comparators. Vaginal delivery was observed more often in MVI arm versus DVI, Dgel, and Dtab. Only in case of Foley frequency of vaginal delivery was lower in the MVI group, although this result was not statistically significant.
Unfortunately, adverse events were not widely reported in the trials. Only for one trial, Wing [9] , it was possible to present a (Tables 2, 3 ). This approach was reasonable, since the main purpose of the project was to estimate anticipated costs related to MVI use in place of alternative technologies in clinical practice in IOL. Therefore, the direction of the outcome, even if not statistically significant, was relevant to reflect differences in costs.
Results of the Retrospective Questionnaire
Market shares of interventions used in IOL in 5
countries of interest revealed a lack of one most commonly chosen option across countries. Prostaglandins were used in the vast majority of cases of IOL in Austria and Slovakia. In Poland only 2 % of IOL was supported by one of the prostaglandins (Dgel). Oxytocin was used in almost all cases of IOL in Romania and often used in Poland and Russia. Balloon catheter was used most often in Poland (Table 4 ).
Costs applied in the economic model are presented in Table 4 .
The hourly cost of stay in wards varied both between countries and ward types. Generally, the most expensive was the labor ward with higher hourly rate for cesarean than vaginal delivery. The cost of stay on antenatal ward was the lowest one (with exception of Austria). On average, Austria and Slovakia had the highest hourly rates whereas Russia had the lowest (Table 4 ).
The length of patient stay on the hospital wards was connected with the local clinical practice. In general, the patient's stay on the postnatal ward was the longest one. In all countries except for Romania, cesarean delivery was related to a longer length of stay than vaginal delivery (the difference was between 4.75 and 74.50 h). In Russia, patient stayed about 11.92 and 16.67 h in total on hospital wards (for vaginal and cesarean delivery, respectively); whereas, at the other end the scale, is Slovakia with 130 and 168.75 h (Fig. 2) .
Time spent by medical staff per patient was reported separately for each specialist. The differences in time devoted by medical staff across countries were noticeable, as it varied from 30 to a maximum of 560 min per nurse (Austria-Romania) and from 155 to 840 min per obstetrician-gynecologist (Austria-Russia) (Fig. 3) .
Results of the Cost-Consequences Model
Results of the cost-consequences model were calculated as cost differences per single patient, separately for two variants of clinical data implementation: (1) numerical and (2) statistically significant values. The results of the model are presented in Table 5 .
Use of MVI in most scenarios was related to a reduction in time consumed by hospital staff, mostly for midwives and obstetrician-gynecologists, and a reduction in the length of patients' stay in hospital wards, especially for the phase between induction and labor and during labor itself (Table 5 ).
Using MVI in place of prostaglandin E2 was less costly in almost all comparisons. The highest cost difference was observed in Austria, where MVI generated savings between €575.15 and €713.42 per patient. Both numerical and statistically significant scenarios showed savings. The exception was Russia, where the total healthcare cost derived from using Dgel was a slightly lower than for MVI in the model variant with statistically significant values. However, the difference was small (€5.36 per patient in favor of Dgel). For Poland, the introduction of MVI in IOL generated additional savings in comparison to Dgel, while the comparison to Foley was related to extra costs, due mostly to the very low cost of the Foley catheter. Data obtained from the questionnaire study; year of the costs-2014 We have identified two systematic reviews, which assess prostaglandins in IOL Thomas [22] and Alfirevic [23] . Unfortunately, neither presents data for MVI. Only the most recent network meta-analysis (Alfirevic [24] ) includes There are only a small number of economic evaluations for prostaglandin used in IOL (Petrou [25] and Baaren [26] ). We cannot relate our results to these studies, because of their scope. We did not find any analysis that assessed costs and effectiveness of using MVI in IOL. In this sense, our analysis is the only economic evaluation which gathers both clinical effectiveness and RWD to estimate the costs and benefits from the use of MVI in place of the current clinical practice.
Our study is especially important, as it presents costs related to IOL from hospital perspective. Cost and resource use data are very often difficult to obtain, therefore this paper gives opportunity to access them. It may be also treated as an overview of the standards applied in other medical centers. 
